Table 1.
Current immunotherapies approved by the FDA
| Approach | Target | Name | Company | Diseases |
|---|---|---|---|---|
| Cytokine (IL-2) | IL-2R | Proleukin (Aldesleukin) | Prometheus Laboratories Inc. | Renal cell carcinoma, and melanoma |
| DC vaccine | PAP | Sipuleucel-T (Provenge) | Dendreon Corporation | Prostate cancer |
| Immune checkpoint blockade | CTLA-4 | Ipilimumab (Yervoy) | Bristol-Myers Squibb | Melanoma, renal cell carcinoma, and colorectal cancer |
| PD-1 | Nivolumab (Opdivo) | Bristol-Myers Squibb | Melanoma, non-small-cell lung cancer, renal cell carcinoma, Hodgkin's lymphoma, head and neck cancer, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, and small cell lung cancer | |
| Pembrolizumab (Keytruda) | Merck | Melanoma, non-small-cell lung cancer, head and neck cancer, Hodgkin's lymphoma, urothelial carcinoma, gastric cancer, cervical cancer, hepatocellular carcinoma, and Merkel cell carcinoma | ||
| Cemiplimab (Libtayo) | Regeneron | Metastatic cutaneous squamous cell carcinoma | ||
| PD-L1 | Atezolizumab (Tecentriq) | Genentech | Bladder cancer, non-small-cell lung cancer, triple-negative breast cancer, and small cell lung cancer | |
| Avelumab (Bavencio) | Merck Serono and Pfizer | Merkel cell carcinoma, urothelial carcinoma | ||
| Durvalumab (Imfinzi) | AstraZeneca | Urothelial carcinoma, non-small-cell lung cancer | ||
| CAR T-cell therapy | CD19 | Axicabtagene ciloleucel (Yescarta) | Kite Pharma | Large B-cell lymphoma |
| Tisagenlecleucel (Kymriah) | Novartis | Acute lymphoblastic leukemia, and large B-cell lymphoma |
Data from FDA website (before 2019 April).
DC, dendritic cells; PAP, prostatic acid phosphatase.